Regarding the industry's talent pipeline, Dr. de Miguel highlights the importance of education programs in the fields of science, technology, engineering, and mathematics (STEM) in building the ...

Recent developments in the biopharma AI world include an alliance between Thermo and Datavant, plus news from Insilico, ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Roy W. Ware, PhD, MBA appointed as Chief Manufacturing and Technology OfficerCaryn Barnett appointed as VP, Clinical ...

Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

Following completion of enrolment, Senti Biosciences plans FDA discussions in 2026 on pivotal registration and new AML ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New ...

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...